The Asian Scientist 100
Can Li
Institution
University of Hong Kong
Country
Hong Kong
Field
Engineering
Li is a recipient of the 2023 Croucher Tak Wah Mak Innovation Award for his research exploring the limitations of digital computers in performing tasks accomplished by the human brain, including recognising faces, reasoning based on vague information, and learning from experience.
(Photo: University of Hong Kong)
AWARDS
- 2023 Croucher Tak Wah Mak Innovation Award
Related articles
Identifiable Human DNA Recovered From Mosquitoes
Human blood extracted from mosquitoes can be used for DNA analysis up to two days after feeding.
An Eco-Friendly Sponge For Soaking Up Oil Spills
Scientists in India have combined cellulose with a gelator to create a sponge that effectively sucks up crude oil.
The Oceans Heat Up As Global Warming Persists
An analysis of three independent datasets confirm that the oceans are warming rapidly.
Antibody May Help Immune System Catch Evasive Ovarian Cancer
Ovarian cancers resistant to existing treatments could be tackled using the PD-1 inhibitory antibody nivolumab, study shows.
Immunologists Awarded Inaugural Tang Prize
Professors Tasuku Honjo and James P. Allison share the inaugural Tang Prize in Biopharmaceutical Sciences, Asia's Nobel Prize equivalent.
Tasuku Honjo Wins 2016 Keio Medical Science Prize
Honjo was recognized for his discovery of PD-1, a negative regulator of immune responses, as well as his subsequent work in the field of immunotherapy.
PD-1 Overexpression Helps Cancer Cells Evade Immune Attack
A genetic alteration that allows cancer cells to evade attack could indicate if expensive antibody treatments are effective for particular patients.
Scientists Discover A Mutation That Prevents Glaucoma
Although other variants of the LOXL1 gene have been linked to glaucoma, the p.Y407F mutation offers a 25-fold protection against the disease.
Celgene Buys The Rights To BeiGene’s Checkpoint Inhibitor
BeiGene will acquire Celgene's commercial operations in China and exclusive license to Celgene's China cancer commercial portfolio.